Galmed Pharmaceuticals (GLMD) Stock Statistics & Valuation Metrics

Galmed Pharmaceuticals has a market cap or net worth of $4.98M. The enterprise value is -$696.37K.

Galmed Pharmaceuticals has 7,684,074 shares outstanding. The number of shares has decreased by -2.65% in one year.

Galmed Pharmaceuticals’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -53.92%.

The current PE Ratio of Galmed Pharmaceuticals is ―. Galmed Pharmaceuticals’s PEG ratio is 0.00446.

In the last 12 months, Galmed Pharmaceuticals had revenue of 0.00 and earned -10.31M in profits. Earnings per share was -2.39.

In the last 12 months, operating cash flow was -6.32M and capital expenditures 0.00, giving a free cash flow of -6.32M billion.

Galmed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Galmed Pharmaceuticals upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).

Galmed Pharmaceuticals as a current ratio of 6.55, with Debt / Equity ratio of 0.00%

In the past 12 months, Galmed Pharmaceuticals has paid 0.00 in taxes.

Galmed Pharmaceuticals EV to EBITDA ratio is 0.07, with an EV/FCF ratio of 0.12.

Galmed Pharmaceuticals has $18.16M in cash and marketable securities with $0.00 in debt, giving a net cash position of $18.16M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Galmed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold